作者:洪玉,徐国兴
作者单位:1中国福建省福州市,福建医科大学附属第二医院;2中国福建省福州市,福建医科大学附属第一医院
【摘要】 目的:观察外伤性PVR大鼠和外伤后应用人工合成基质金属蛋白酶抑制剂(GM6001)中大鼠视网膜组织MMP1、MMP3及TIMP1在不同病程中的表达变化。
方法:将180只SD大鼠随机分为正常对照组、外伤性PVR组和外伤后应用GM6001组。应用免疫组化法在不同时间对各组大鼠视网膜组织MMP1、MMP3及TIMP1的表达进行定性、定位、半定量检测。
结果:1)MMP1、MMP3、TIMP1主要表达于视网膜组织的视锥视杆层、视网膜外网状层、视网膜内网状层、神经纤维层。2)各个亚组在正常对照组、外伤后应用GM6001组MMP1、MMP3微弱表达。3)MMP3在外伤性PVR组1,3,7d显著表达, MMP1在外伤性PVR组3, 7,14d显著表达 (P<0.05)。TIMP1在外伤性PVR组与外伤后应用GM6001组的各个亚组均有明显表达(P<0.01)。MMP3/TIMP1的比率在外伤性PVR组1,3,7d增高 (P<0.05)。MMP1/TIMP1的比率在外伤性PVR组3,7,14d增高 (P<0.05)。
结论:MMP1、MMP3与PVR形成的病理过程有关,TIMP1与二者特异性结合抑制其活性。GM6001通过调节MMP1/TIMP1 和MMP3/TIMP1达到平衡,能抑制PVR的发生和发展,干预PVR的发展进程。
【关键词】 基质金属蛋白酶1;基质金属蛋白酶3;基质金属蛋白酶抑制剂1;GM6001;外伤性增生性玻璃体视网膜病变;免疫组化
Research on the effect of MMP1, MMP3, TIMP1 on the traumatic PVR
Yu Hong1,2, GuoXing Xu2
Foundation items: Science Reserch Foundation of Ministory of Health (No.WKJ20052013); Natural Science Research Foundation of Fujian Province (No.C0510015); Professor Development Fund of Fujian Medical University (No.2006js6033)
1 The Second Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China; 2 The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China
Abstract
AIM: To investigate the expression of MMP1, MMP3 and TIMP1 during the course of traumatic PVR treated with GM6001 and without GM6001.
METHODS: Totally 180 SD rats were divided randomly into three groups: normal control group, the traumatic PVR group, the traumatic PVR treated with GM6001 group. The expression of MMP1, MMP3 and TIMP1 were qualitative and semiquantitative analysised with immunohistochemistry at different times.
RESULTS: 1) Immunohistochemistry showed that the expression of MMP1, MMP3 and TIMP1 were mainly located in the photoreceptor cells layer, out plexiform layer, inner plexiform layer and nerve fiber layer. 2) The expression of MMP1 and MMP3 in the normal group and the traumatic PVR treated with GM6001 group were weak at all time. 3) The expression of MMP3 in the traumatic PVR group was strong at day 1, 3 and 7. The expression of MMP3 in the traumatic PVR group was strong at day 3, 7 and 14 (P<0.05). The expression of TIMP1 in the traumatic PVR group and the traumatic PVR treated with GM6001 group were strong at all time (P<0.01). The rate of MMP3/TIMP1 in the traumatic PVR group increased at day 1, 3 and 7 (P<0.05). The rate of MMP1/TIMP1 in the traumatic PVR group increased at day 3, 7 and 14 (P<0.05).
CONCLUSION: MMP1 and MMP3 play key role in the course of traumatic PVR. TIMP1 binds specifitly to MMP1 and MMP3 and suppressed their activity. GM6001 plays an important role in the course of traumatic PVR prevention and treatment by regulating the rate of MMP1/TIMP1 and MMP3/TIMP1.
KEYWORDS: matrix metalloproteinase1; matrix metalloproteinase3; tissue inhibitors of metalloproteinase1; GM 6001;proliferative vitreoretinopathy; immunohistochemistry
Hong Y, Xu GX. Research on the effect of MMP1, MMP3, TIMP1 on the traumatic PVR. Int J Ophthalmol (Guoji Yanke Zazhi) 2008;8(11):21952198
0引言
近年来研究表明在外伤性增生性玻璃体视网膜病变(proliferative vitreoretinopathy, PVR)病理过程中基质金属蛋白酶(matrix metalloproteinases,MMPs)与基质金属蛋白酶抑制剂(tissue inhibitor of matrix metalloproteinases, TIMPs)系统起着重要作用。GM6001又名Galardon或ilomastat,是已知作用最强的合成的基质金属蛋白酶抑制剂,可防治外伤性PVR形成。目前国内外关于MMPs及TIMPs与外伤性PVR的关系研究只有零星报告。本课题应用免疫组织化学染色等方法从组织、细胞水平定性、定位、半定量MMP1、MMP3及TIMP1在正常眼球和外伤性PVR眼球及外伤后应用人工合成基质金属蛋白酶抑制剂治疗眼球中的表达量及其在眼球内的分布情况。为探讨眼外伤PVR的发病机制及人工合成基质金属蛋白酶抑制剂治疗和预防外伤性PVR机制,评价人工合成基质金属蛋白酶抑制剂治疗和预防外伤性PVR的疗效,为临床应用人工合成基质金属蛋白酶抑制剂预防和治疗外伤性PVR提供实验基础。
1.材料和方法
1.1材料 雄性清洁级spraguedawley (SD)大鼠180只,体质量250±25g,由上海斯莱克实验动物有限责任公司提供人工合成基质金属蛋白酶抑制剂(GM6001)、MMP1抗体(sc21731)、MMP3抗体(sc6839)、TIMP1抗体(sc6834)、PV6002试剂盒、SP9003试剂盒、DAB显色试剂盒、檬酸抗原修复液、多聚赖氨酸玻片、PBS、过氧化酶阻断剂等。25微升显微注射器、BH2 OLMPUS光学显微镜、石蜡切片机( LKBNova 5型)彩色图像分析仪(Image8000)、台式低速离心机(Kendro Biofuge stratos)科峻仪器公司、微量移液器、超级微量恒温器(HW8B型)。
1.2方法 取枸橼酸2.73g,枸橼酸三钠4.48g,葡萄糖2g,蒸馏水100mL,配成l00mL ACD溶液,高压灭菌后备用。取250g左右SD大鼠,从鼠尾采血1mL,与1/l0体积的ACD抗凝剂混合,低速(1000r/min)离心10min,吸取上层液即为自体富含血小板血浆(Plateletrich plasms, PRP)。将250g左右SD大鼠180只,随机分为正常对照组(A)、外伤性PVR组(B)和外伤后应用GM6001组(C),每组60只。左眼为实验眼,右眼为自身对照眼。常规麻醉,散瞳,消毒铺巾,暴露左眼,在显微镜观察下,用微量注射器从颞上方睫状体扁平部即距角膜缘后2mm处向玻璃体腔内、视盘前方注入生理盐水20μL。第14d重复注射一次,即制备A组动物模型。注入已准备好的PRP血浆20μL。第14d注射生理盐水20μL,即制备B组动物模型。注入已准备好的PRP血浆20μL,外伤后12h向玻璃体腔内、视盘前方注射20μL(100μmol/L)GM6001。第14d重复注射一次,即制备C组动物模型。各组再随机分为6个亚组: 1,3,7,14,21d和28d,每亚组10只(10眼)。三组大鼠分别在1,3,7,14,21d和28d静脉注射戊巴比妥钠(60mg/kg);处死A、B、C组每亚组各10只动物后,立即取出左眼球,于锯齿缘后 0.5mm处剪开眼球壁,去除眼前节,分离视网膜放于40g/L甲醛溶液中固定,石蜡包埋、连续切片。MMP1的免疫组化采用二步法,MMP3、TIMP1的免疫组化采用SP法。
统计学处理:采用Image8000彩色图像分析仪对各组免疫组化切片进行分析,对图像中阳性反应部位(胞浆)进行平均灰度和面密度分析。记录相应数据,取其平均值作为该标本的结果,并对结果进行统计学检验。所有统计均在SPSS 11.5软件上运行,计量资料以均数±标准差(±s)表示,进行单因素方差分析,以P<0.05作为差异有统计学意义的检验标准。
[1] [2] 下一页 |